세계의 미토콘드리아 근병증 진단과 치료 시장은 2030년까지 3,750만 달러에 달할 전망
2024년에 2,720만 달러로 추정된 미토콘드리아 근병증 진단과 치료 시장은 2030년에는 3,750만 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 5.5%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 미토콘드리아 근병증 치료는 CAGR 6.7%를 기록하며, 분석 기간 종료까지 2,400만 달러에 달할 것으로 예측됩니다. 미토콘드리아 근병증 진단 검사 분야의 성장률은 분석 기간 중 CAGR 3.6%로 추정됩니다.
미국 시장은 710만 달러로 추정, 중국은 CAGR 5.4%로 성장 예측
미국의 미토콘드리아 근병증 진단과 치료 시장은 2024년에 710만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 600만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 5.4%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 5.3%와 4.6%로 예측됩니다. 유럽에서는 독일이 CAGR 4.3%로 성장할 것으로 예측됩니다.
세계의 미토콘드리아 근병증 진단과 치료 시장 - 주요 동향과 촉진요인 정리
미토콘드리아 근병증 진단과 치료가 탄력을 받는 이유는 무엇인가?
미토콘드리아 근병증 진단과 치료는 희귀 유전성 질환에 대한 인식이 높아지고 환자의 삶의 질에 큰 영향을 미치기 때문에 최근 주목받고 있습니다. 근육과 신경세포의 에너지 생산 장애를 특징으로 하는 미토콘드리아 근병증은 만성 피로, 근력 저하, 장기 기능 장애의 중요한 원인으로 인식되고 있습니다. 이러한 인식 증가로 인해 의료 서비스 프로바이더 및 연구는 첨단 유전자 및 생화학 검사를 통한 조기 및 정확한 진단에 중점을 두게 되었습니다. 또한 옹호 단체와 조직은 특히 선진국에서 인지도를 높이고 진단 서비스에 대한 접근성을 개선하는 데 중요한 역할을 하고 있습니다. 이러한 질병에 대한 이해도가 높아지고 혁신적인 진단 툴이 사용 가능해짐에 따라 더 나은 관리와 치료 결과를 위한 길이 열리고 있습니다.
유전자 검사의 발전은 진단을 어떻게 변화시키고 있는가?
유전자 검사의 기술적 발전은 미토콘드리아 근병증 진단에 혁명을 가져왔으며, 근본적인 유전자 돌연변이를 보다 신속하고 정확하게 식별할 수 있게 되었습니다. 차세대 염기서열 분석(NGS) 플랫폼은 미토콘드리아 DNA 돌연변이 검출의 기초가 되어 보다 저렴한 비용으로 종합적인 분석이 가능해졌습니다. 또한 전체 엑솜 및 전체 유전체 시퀀싱의 혁신은 이러한 질환의 유전적 기반에 대한 더 깊은 인사이트을 제공하고, 보다 표적화된 치료적 개입을 용이하게 하고 있습니다. 생화학 분석 및 자기공명분광법과 같은 첨단 이미징 기술은 미토콘드리아 기능 장애의 기능적 영향을 측정함으로써 진단의 정확성을 더욱 높이고 있습니다. 이러한 발전은 조기 진단을 향상시킬 뿐만 아니라 맞춤 치료 접근에 필수적인 환자 분류를 개선하는 데에도 도움이 되고 있습니다. 결과적으로, 이러한 첨단 진단 기술의 채택은 미토콘드리아 근병증 시장의 성장을 가속하고 있습니다.
치료 옵션의 발전에서 치료 개발은 어떤 역할을 하는가?
미토콘드리아 근병증 치료법은 단순히 증상을 완화하는 것이 아니라 질병의 근본 원인을 해결하는 것을 목표로 하는 새로운 치료법의 출현으로 진화하고 있습니다. 유전자 치료는 큰 잠재력을 가지고 있으며, 미토콘드리아 DNA의 돌연변이를 교정하고 정상적인 세포 기능을 회복시키는 데 초점을 맞춘 연구가 현재 진행 중입니다. 또한 미토콘드리아의 생합성을 촉진하고 에너지 생산을 개선하는 저분자 약물의 개발도 진행되고 있습니다. 코엔자임 Q10과 L-카르니틴 보충제를 포함한 영양학적 개입은 증상을 완화하고 환자의 건강을 개선하기 위해 치료 요법에 통합되고 있습니다. 미토콘드리아 대체요법과 같은 혁신적인 치료 전략을 모색하는 임상시험은 장기적인 해결책에 대한 희망을 가져다주고 있습니다. 연구개발에 대한 투자 확대와 학계와 생명공학 기업 간의 협력에 힘입어 이러한 발전은 환자들이 이용할 수 있는 치료 옵션을 크게 확장하고 있습니다.
미토콘드리아 근병증 진단 및 치료 시장의 성장 원동력은?
미토콘드리아 근병증 진단 및 치료 시장의 성장은 여러 요인에 의해 주도되고 있습니다. 유전성 질환의 유병률 증가와 조기 및 정확한 진단에 대한 관심이 높아지면서 고급 유전자 검사 및 생화학 분석에 대한 수요가 증가하고 있습니다. 특히 유전자 치료 및 미토콘드리아 대체 기술 분야에 대한 연구개발에 대한 투자가 증가하면서 효과적인 치료 솔루션을 위한 새로운 길이 열리고 있습니다. 또한 신흥 시장에서의 진단 서비스 이용 가능성의 확대는 의료 인프라를 강화하는 정부 구상과 함께 의료 접근성을 확대하는 데 기여하고 있습니다. 환자 옹호 단체와 비영리 단체도 인지도를 높이고 치료의 진전을 가속화하기 위한 협력을 촉진하는 데 중요한 역할을 하고 있습니다. 이러한 촉진요인들이 결합되어 미토콘드리아 근병증 진단과 치료를 변화시키고 이 쇠약해진 질환을 앓고 있는 환자와 가족들에게 희망을 줄 수 있는 시장의 잠재력을 강조하고 있습니다.
부문
유형(치료 유형, 진단 테스트);질환(MELAS 질환, 리 증후군 질환, 미토콘드리아 DNA 결손 증후군(MDS) 질환, KSS(Kearns-Sayre Syndrome) 질환, 기타 질환)
조사 대상 기업의 예(총 52건)
Abcam Plc
Abliva
Biogen, Inc.
Blueprint Genetics OY
Centogene AG
GeneDx
GenSight Biologics
Kaneka Corporation
Khondrion
Stealth BioTherapeutics
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장의 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global Mitochondrial Myopathies Diagnosis and Treatment Market to Reach US$37.5 Million by 2030
The global market for Mitochondrial Myopathies Diagnosis and Treatment estimated at US$27.2 Million in the year 2024, is expected to reach US$37.5 Million by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Mitochondrial Myopathies Treatment, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$24.0 Million by the end of the analysis period. Growth in the Mitochondrial Myopathies Diagnostic Tests segment is estimated at 3.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$7.1 Million While China is Forecast to Grow at 5.4% CAGR
The Mitochondrial Myopathies Diagnosis and Treatment market in the U.S. is estimated at US$7.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.0 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.
Global Mitochondrial Myopathies Diagnosis and Treatment Market - Key Trends & Drivers Summarized
Why Is Mitochondrial Myopathies Diagnosis and Treatment Gaining Momentum?
The diagnosis and treatment of mitochondrial myopathies have garnered increased attention in recent years due to the rising awareness of rare genetic disorders and their profound impact on patients' quality of life. Mitochondrial myopathies, characterized by energy-production deficits in muscle and nerve cells, are being recognized as significant contributors to chronic fatigue, muscle weakness, and organ dysfunction. This increased awareness has encouraged healthcare providers and researchers to focus on early and accurate diagnosis through advanced genetic testing and biochemical assays. Moreover, advocacy groups and organizations are playing a crucial role in spreading awareness and improving access to diagnostic services, particularly in developed regions. The growing understanding of these disorders and the availability of innovative diagnostic tools are paving the way for better management and treatment outcomes.
How Are Advancements in Genetic Testing Transforming Diagnosis?
Technological advancements in genetic testing are revolutionizing the diagnosis of mitochondrial myopathies, enabling faster and more precise identification of underlying genetic mutations. Next-generation sequencing (NGS) platforms have become a cornerstone in detecting mitochondrial DNA mutations, allowing for comprehensive analyses at a lower cost. Additionally, innovations in whole-exome and whole-genome sequencing are providing deeper insights into the genetic basis of these disorders, facilitating more targeted therapeutic interventions. Biochemical assays and advanced imaging techniques, such as magnetic resonance spectroscopy, are further enhancing diagnostic accuracy by measuring the functional impact of mitochondrial dysfunction. These advancements not only improve early diagnosis but also aid in better patient stratification, essential for personalized treatment approaches. As a result, the adoption of these cutting-edge diagnostic technologies is driving the growth of the mitochondrial myopathies market.
What Role Do Therapeutic Developments Play in Advancing Treatment Options?
The treatment landscape for mitochondrial myopathies is evolving with the emergence of novel therapies aimed at addressing the root causes of the disease rather than just alleviating symptoms. Gene therapy holds immense potential, with ongoing research focusing on correcting mitochondrial DNA mutations and restoring normal cellular function. Additionally, the development of small-molecule drugs that enhance mitochondrial biogenesis and improve energy production is gaining traction. Nutritional interventions, including coenzyme Q10 and L-carnitine supplements, are being integrated into treatment regimens to mitigate symptoms and improve patient well-being. Clinical trials exploring innovative therapeutic strategies, such as mitochondrial replacement therapy, are providing hope for long-term solutions. These advancements, supported by increased investments in R&D and collaborations between academic institutions and biotech firms, are significantly expanding the treatment options available to patients.
What Is Driving Growth in the Mitochondrial Myopathies Diagnosis and Treatment Market?
The growth in the mitochondrial myopathies diagnosis and treatment market is driven by several factors. The increasing prevalence of genetic disorders and a growing emphasis on early and accurate diagnosis have spurred demand for advanced genetic testing and biochemical assays. Rising investments in R&D, particularly in the field of gene therapy and mitochondrial replacement techniques, are opening new avenues for effective treatment solutions. Moreover, the expanding availability of diagnostic services in emerging markets, coupled with government initiatives to enhance healthcare infrastructure, is broadening access to care. Patient advocacy groups and non-profit organizations are also playing a critical role in driving awareness and facilitating collaborations to accelerate therapeutic advancements. Together, these drivers underscore the market's potential to transform the diagnosis and treatment of mitochondrial myopathies, offering hope to patients and families affected by these debilitating conditions.
SCOPE OF STUDY:
The report analyzes the Mitochondrial Myopathies Diagnosis and Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Treatment Type, Diagnostic Tests); Disease (MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease, Other Diseases)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Mitochondrial Myopathies Diagnosis and Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advancements in Genetic Testing Techniques Propel Mitochondrial Myopathy Diagnosis
Increasing Focus on Personalized Medicine Boosts Demand for Targeted Therapies
Rising Awareness About Mitochondrial Diseases Fuels Diagnostic Market Growth
Growth in Research Activities on Mitochondrial Dysfunction Drives Innovation
Development of Novel Drug Therapies Expands Treatment Opportunities
Integration of AI and Machine Learning in Diagnosis Enhances Accuracy
Growing Use of Biomarker-Based Diagnostic Tools Propels Market Demand
Demand for Early Diagnosis Drives Growth in Genetic Counseling Services
Expanding Clinical Trials for Mitochondrial Myopathy Therapies Boosts Market Potential
Increasing Government and Private Funding for Rare Disease Research Fuels Growth
Role of Patient Advocacy Groups in Driving Awareness and Adoption of Treatments
Advancements in Supportive Care Solutions Improve Quality of Life for Patients
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Mitochondrial Myopathies Diagnosis and Treatment Market Analysis of Annual Sales in US$ for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Treatment Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for Treatment Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Diagnostic Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for Diagnostic Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for MELAS Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for MELAS Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Leigh Syndrome Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for Leigh Syndrome Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Mitochondrial DNA Depletion Syndrome (MDS) Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 13: World 6-Year Perspective for Mitochondrial DNA Depletion Syndrome (MDS) Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Kearns-Sayre Syndrome (KSS) Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 15: World 6-Year Perspective for Kearns-Sayre Syndrome (KSS) Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 17: World 6-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Mitochondrial Myopathies Diagnosis and Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 18: USA Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 19: USA 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 20: USA Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 21: USA 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
CANADA
TABLE 22: Canada Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 23: Canada 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 24: Canada Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 25: Canada 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
JAPAN
Mitochondrial Myopathies Diagnosis and Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 27: Japan 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 28: Japan Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 29: Japan 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
CHINA
Mitochondrial Myopathies Diagnosis and Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 30: China Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 31: China 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 32: China Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 33: China 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
EUROPE
Mitochondrial Myopathies Diagnosis and Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 34: Europe Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 35: Europe 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 36: Europe Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 37: Europe 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 38: Europe Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 39: Europe 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
FRANCE
Mitochondrial Myopathies Diagnosis and Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 40: France Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 41: France 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 42: France Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 43: France 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
GERMANY
Mitochondrial Myopathies Diagnosis and Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 44: Germany Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 45: Germany 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 46: Germany Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 47: Germany 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
ITALY
TABLE 48: Italy Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 49: Italy 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 50: Italy Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 51: Italy 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
UNITED KINGDOM
Mitochondrial Myopathies Diagnosis and Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 52: UK Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 53: UK 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 54: UK Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 55: UK 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 57: Rest of Europe 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 59: Rest of Europe 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
ASIA-PACIFIC
Mitochondrial Myopathies Diagnosis and Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 61: Asia-Pacific 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 63: Asia-Pacific 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
REST OF WORLD
TABLE 64: Rest of World Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Type - Treatment Type and Diagnostic Tests - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 65: Rest of World 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Treatment Type and Diagnostic Tests for the Years 2025 & 2030
TABLE 66: Rest of World Recent Past, Current & Future Analysis for Mitochondrial Myopathies Diagnosis and Treatment by Disease - MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 67: Rest of World 6-Year Perspective for Mitochondrial Myopathies Diagnosis and Treatment by Disease - Percentage Breakdown of Value Sales for MELAS Disease, Leigh Syndrome Disease, Mitochondrial DNA Depletion Syndrome (MDS) Disease, Kearns-Sayre Syndrome (KSS) Disease and Other Diseases for the Years 2025 & 2030
